{"prompt": "['REduCing Immunogenicity to PegloticasE (RECIPE)', 'Protocol #Version v12: 13Jan2020', '7.2.4 PRODUCT DESTRUCTION', 'The study sites will maintain an inventory of drug supplies received and dispensed. UAB will provide forms to document', 'all inventory transactions. Upon completion or termination of the study, all unused drug supplies, will be destroyed with', 'written certification confirming destruction within sixty (60) days of study completion or expiration of the study drug.', '7.2.5 PREPARATION', 'Mycophenolate Mofetil (MMF)', 'Mycophenolate Mofetil (MMF) capsules include croscarmellose sodium, magnesium stearate, povidone (K-90) and', 'pregelatinized starch. The MMF capsule shells contain black iron oxide, FD&C blue #2, gelatin, red iron oxide, silicon', 'dioxide, sodium lauryl sulfate, titanium dioxide, and yellow iron oxide. All MMF capsules will be over-encapsulated with', 'cellulose to match compounded placebo. Favorable pharmacokinetic properties of the encapsulation process have been', 'consistently noted with other substances.', 'Pegloticase', 'Pegloticase vials will be visually inspected for particulate matter and discoloration before administration, whenever', 'solution and container permit. Vials will not be used if either is present. Using appropriate aseptic technique, 1 mL of', 'pegloticase will be withdrawn from the vial into a sterile syringe. Any unused portion of product remaining in the vial will', 'be discarded. Syringe contents will be injected into a single 250 mL bag of 0.45% or 0.9% Sodium Chloride Injection,', 'United States Pharmacopeia (USP) for IV infusion and will not be mixed or diluted with other drugs. The infusion bag', 'containing the dilute pegloticase solution will be inverted a number of times to ensure thorough mixing, but will not be', 'shaken. Pegloticase-diluted in infusion bags is stable for 4 hours at 2\u00b0C to 8\u00b0C (36\u00b0F to 46\u00b0F) and at room temperature', '(20\u00b0C to 25\u00b0C, 68\u00b0F to 77\u00b0F); however, the diluted solution will be stored under refrigeration, not frozen, protected from', 'light, and used within 4 hours of dilution. Before administration, the diluted solution of pegloticase will be allowed to', 'reach room temperature. Pegloticase in a vial or IV infusion fluid will never be subjected to artificial heating.', '7.3 MEASURES TO MINIMIZE BIAS: RANDOMIZATION AND BLINDING', 'Participants will be randomized 3:1 to either pegloticase + MMF (Peg+MMF) or to pegloticase + placebo (peg+PBO).', 'Randomization allocation will be balanced in time and by site to achieve 24 peg+MMF and 8 peg+PBO using a double-', 'blind design. Treatment assignment will be determined by a random number generator and stratified by site using a', 'central randomization system to ensure the 24/8 allocation. If any concerns arise during the randomization procedures,', 'both the pharmacist and study coordinator will contact the Data Coordinating Center (DCC) at UAB. The UAB IDS will be', 'responsible for assignment of randomization sequence. A drug log will be used to track the study drug from pharmacy', 'to each randomized study participant. The centralized management of the medication will allow maintenance of a', 'double-blind trial.', 'As all participants and study investigators will be blinded to treatment assignment. If there is a serious adverse event,', 'then unblinding will be discussed and if deemed necessary to unblind the participant, then the ID of the unblinded', 'participant, reasons for unblinding, name of the pharmacist and a list of whomever becomes unblinded will be kept in', 'the study binder and centrally at the Data Coordinating Center and Central Pharmacy. The pharmacist will contact that', \"participant's primary physician about the exposure. If necessary, the participant will be withdrawn from the study.\", 'NIAMS and the DSMB via KAI will be informed of any unexpected unblinding via email or at the scheduled DSMB', 'meetings.', '7.4', 'STUDY INTERVENTION COMPLIANCE', '13']['REduCing Immunogenicity to PegloticasE (RECIPE)', 'Protocol #Version v12: 13Jan2020', 'Adherence to the medication will be recorded by pill counts at the follow-up study visits and consumption of at least', '80% will be required to consider the participant compliant. A non-compliant participant will continue in the study and', 'enter analyses as mandated by statistician. Pill counts and infusion log will be used to calculate study intervention', 'compliance. Other issues of non-adherence to study procedures will be reinforced with participants at study visits and', 'recurrent non-adherence will lead to study discontinuation.', '7.5 CONCOMITANT THERAPY', 'Concomitant medications are defined as drug or biological products other than the study drug(s) taken by a participant', 'during the clinical trial. This includes other prescription medications (including preventive vaccines), over-the-counter', \"medications, herbal medications, vitamins, and food supplements. A comprehensive list of participant's concomitant\", 'medications will be collected at baseline and at V2, V3, V5, V7-V17 each visit. This will include the name of the', 'drug/vitamin/supplement, dose, route of administration, start and stop dates, and the reason for which the medication', 'was taken. All medications will be listed by participant using the generic name(s) of the drug/vitamin/supplement.', 'Serious adverse events related to the use of a concomitant drug/vitamin/supplement will be documented on the', 'appropriate AE eCRF.', 'Prior to participation in RECIPE participants will be instructed to stop their current urate lowering therapy.', '7.5.1 RESCUE MEDICINE', 'There is no specific rescue medication for mycophenolate adverse events. Overdose of MMF will be managed with', 'prompt decontamination via activated charcoal, symptomatic management of nausea and vomiting along with adequate', 'hydration. 54 Adverse effects associated with MMF are subsequently reviewed in section 8.3.3.3.', 'All participants will receive prophylactic treatment to reduce the risk of acute gout flares, unless medically', 'contraindicated or not tolerated as noted in the FDA-approved pegloticase full prescribing information. The participant', 'will begin a regime of colchicine (0.6mg/day) or Non steroidal anti-inflammatory drug prophylaxis at least 1 week before', 'the first dose of pegloticase and it will continue for the duration of pegloticase therapy. Colchicine prophylaxis will not', 'be interrupted during the course of the clinical trial unless medically contraindicated or if the participant becomes', 'intolerant of colchicine, regardless of whether a gout flare occurs.', 'At the discretion of the investigator, patients still having insufficient relief with colchicine (0.6mg/day) or Non steroidal', 'anti-inflammatory drug prophylaxis are allowed to take oral prednisone, prednisolone or equivalent at a dose up to 20', 'mg/day for a maximum of 7 days.', '8', 'STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT DISCONTINUATION/WITHDRAWAL', '8.1', 'DISCONTINUATION OF STUDY INTERVENTION', 'Due to the risk of anaphylaxis and IRs being higher in patients who have lost therapeutic response, participants with two', 'consecutive serum urate levels above 6 mg/dL shall be classified as a non-responder and discontinued from the study.', 'Investigators will obtain a pre-dose serum urate sample for all patients and review results to verify the serum urate level', 'is < 6 mg/dL prior to infusion.', 'Discontinuation from the study intervention does not mean discontinuation from the study, and remaining study', '14']\n\n###\n\n", "completion": "END"}